Health Canada has issued an alert after Gore identified, through quality‑control testing, that a subset of its VIABAHN® endoprosthesis devices were processed using equipment that was operating outside the validated range. This condition could potentially lead to an incorrect bonding location of the distal tip onto the delivery catheter.
Manufacturers and users are advised to review the affected product batches and follow any further guidance from Health Canada regarding corrective actions or product handling.
Actualités réglementaires4 sept. 2026•1 min de lecture
Gore VIABAHN® Device Quality Issue Identified
Gore discovered some VIABAHN® devices were processed on equipment outside validated range, risking incorrect distal tip bonding.
Compilé par l'équipe PharmaCountry · Source : Health Canada
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note